Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo

Contraception

Volumn 78, Issue 2, 2008, Pages 113-119

  Poindexter, Alfred ^a   Reape, Kathleen Z ^b   Hait, Howard ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Duramed Research Inc   (United States)

Author keywords

Desogestrel; Hormone free interval; Low dose estrogen; Oral contraception

Indexed keywords

ORAL CONTRACEPTIVE AGENT; PLACEBO;

ADULT; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NEUROLOGIC DISEASE; ORAL CONTRACEPTION; PREGNANCY RATE; PROSPECTIVE STUDY; RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; CONTRACEPTIVES, ORAL, SEQUENTIAL; DESOGESTREL; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; METRORRHAGIA; PREGNANCY; TREATMENT OUTCOME;

EID: 47849123301     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.04.001     Document Type: Article

References (16)

1. Van Heusden A., and Fauser B. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 8 (2002) 345-358
2. Baerwald A.R., and Pierson R.A. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can 26 (2004) 19-24
3. Baerwald A.R., Olatunbosun O.A., and Pierson R.A. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 70 (2004) 371-377
4. Fauser B., and Van Heusden A. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 18 (1997) 71-106
5. Willis S.A., Kuehl T.J., Spiekerman A.M., and Sulak P.J. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74 (2006) 100-103
6. Killick S.R., Fitzgerald C., and Davis A. Ovarian activity in women taking an oral contraceptive containing 20 mcg ethinyl estradiol and 150 mcg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 179 (1998) S18-S24
7. Schlaff W., Lynch A., Hughes H., et al. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol 190 (2004) 943-951
8. Reape K.Z., DiLiberti C.E., Hendy C., and Volpe E.J. Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive. Contraception 77 (2008) 34-39
9. Mircette [NDA 20 713] Montvale (NJ): Duramed Research, Inc.; 1998. Available at: http://www.fda.gov/cder/foi/nda/98/20713.htm. [Accessed January 29, 2008].
10. Archer D.F., Jensen J.T., Johnson J.V., Borisute H., Grubb G.S., and Constantine G.D. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception 74 (2006) 439-445
11. Nakajima S.T., Archer D.F., and Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 mg (Loestrin Fe). Contraception 75 (2007) 16-22
12. Anderson F.D., Gibbons W., and Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 73 (2006) 229-234
13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives; collaborative reanalysis of individual data on 53,597 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347 (1996) 1713-1727
14. Marchbanks P.A., McDonald J.A., Wilson H.G., et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 346 (2002) 2025-2032
15. Hannaford P.C., Selvaraj S., Elliott A.M., Angus V., Iversen L., and Lee A.J. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. Br Med J 335 (2007) 651
16. ACOG Practice Bulletin, Number 42, April 2003. Breast Cancer Screening. Available at: http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=3990 [Accessed February 13, 2008].